Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR

Core Viewpoint - A class action lawsuit has been filed against Capricor Therapeutics, Inc. for allegedly making false and misleading statements regarding its drug candidate, deramiocel, during the class period from October 9, 2024, to July 10, 2025 [1][2]. Summary by Relevant Sections Class Action Details - The lawsuit claims that Capricor misrepresented the progress of its deramiocel drug candidate towards FDA approval, despite being aware of negative data from its Phase 2 HOPE-2 trial [2]. - The deadline for shareholders to join the class action is September 15, 2025 [2]. Shareholder Participation - Shareholders who purchased shares of CAPR during the specified class period are encouraged to contact the law firm for potential lead plaintiff appointments, although this is not necessary to participate in any recovery [2][3]. - Registered shareholders will receive updates through a portfolio monitoring software at no cost [3]. Law Firm Background - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4].